RIVFLOZA (Nedosiran Sodium) Patent Expiration, LOE Window & CMS Spending
RIVFLOZA (Nedosiran Sodium) by Novo Nordisk: FDA Orange Book core substance LOE 2038-10-12, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $62,880 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novo Nordisk |
| FDA Application & Pathway | N215842 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2038-10-12 |
| Last Listed Patent or Exclusivity Date | 2038-10-12 |
| Orange Book Patents (*PED Extensions) | 18 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($62,880 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.